Key result
Early AT1 receptor blockade with SR/BMS in spontaneously hypertensive rats limited genetic hypertension development and cardiovascular remodeling during treatment and persistently after withdrawal.
Why the study?
Does early AT1 receptor blockade with SR 47436/BMS-186295 limit genetic hypertension development and cardiovascular remodeling in spontaneously hypertensive rats?
Does early AT1 receptor blockade with SR 47436/BMS-186295 limit genetic hypertension development and cardiovascular remodeling in spontaneously hypertensive rats?
Early AT1 receptor blockade in spontaneously hypertensive rats prevents the development of genetic hypertension and cardiovascular remodeling, with effects persisting even after treatment withdrawal.
Answers are grounded in this paper and cite their sources.
Preclinical data do not change practice; leaves open whether early AT1 blockade alters human genetic hypertension trajectories.
OBJECTIVE: To investigate the haemodynamic and morphological effects resulting from the chronic administration to young spontaneously hypertensive rats (SHR) of a new selective angiotensin II subtype 1 (AT1) receptor antagonist, SR 47436/BMS-186295 (SR/BMS) both during and after the treatment period. METHODS: SR/BMS (60 mg/kg per day, orally) or distilled water was chronically (from 4 to 20 weeks of age) administered to SHR. At age 8, 14, 20 and 28 weeks the effects of SR/BMS on the systemic and regional haemodynamic (radioactive microsphere technique) and the cardiac and vascular morphological parameters (automatic image analysis) were investigated. RESULTS: SR/BMS limited genetic hypertension development and opposed the age-related rises in total peripheral and regional vascular resistances. Simultaneously, it limited the age-related increases in heart weight, left ventricular cross-sectional area and collagen content. Age-related increases in aortic media thickness and amount of collagen were also significantly reduced, whereas aortic compliance was increased. Eight weeks after withdrawal of treatment the antihypertensive effect of SR/BMS, although attenuated, and the limitation of cardiac and vascular remodelling, persisted. CONCLUSIONS: Early AT1 receptor blockade in SHR opposes genetic hypertension development during the treatment period and persistently after its interruption. Prevention of genetic hypertension development during the treatment period can be accounted for by the limitation of the age-related development of the haemodynamic and morphological abnormalities, whereas the persistence of the antihypertensive effect observed after drug withdrawal is due mainly to a maintained prevention of the development of the cardiovascular morphological alterations.
No takes yet. Share an insight, caveat, or question.
Vacher et al. (1995) studied genetic hypertension. SR 47436/BMS-186295 (SR/BMS) vs. distilled water was evaluated on systemic and regional haemodynamic and cardiac and vascular morphological parameters. Early AT1 receptor blockade with SR/BMS in spontaneously hypertensive rats limited genetic hypertension development and cardiovascular remodeling during treatment and persistently after withdrawal.
Synapse has enriched 10 related papers. Consider them for comparative context: